Erectile dysfunction associated with CV events, all-cause mortality
Patients with erectile dysfunction (ED) have a 44% increased risk of cardiovascular (CV) events, according to a study, published online in Circulation: Cardiovascular Quality and Outcomes.
Patients with erectile dysfunction (ED) have a 44% increased risk of cardiovascular (CV) events, according to a study, published online in Circulation: Cardiovascular Quality and Outcomes.
The study was led by Charalambos Vlachopoulos, MD, with Athens Medical School in Athens, Greece.
ED patients also have a 25% increased risk of all-cause mortality, a 62% increased risk of myocardial infarction (MI), and a 39% increased risk of cerebrovascular events, compared to patients without ED.
“Our results stress the importance of early diagnosis of ED and the meticulous cardiovascular investigation that is required in specific groups of ED patients,” Vlachopoulos wrote.
The relative risk of CV events was higher in younger patients and in intermediate-risk groups. “This is particularly important because this intermediate-risk group is in need of further reclassification with a predictor such as ED,” Vlachopoulous wrote.
The researchers analyzed 14 studies with 92,000 participants.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Are PBMs Putting GLP-1 Drugs on Their Formularies?
October 11th 2024PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Read More
